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Introduction: Enzastaurin is an oral serine/threonine kinase inhib-
itor that targets protein kinase C-beta (PKC-) and the phosphati-
dylinositol-3-kinase/AKT pathway. This trial assessed pemetrexed-
carboplatin  enzastaurin to docetaxel-carboplatin in advanced
non-small cell lung cancer.
Methods: Patients with stage IIIB (with pleural effusion) or IV
non-small cell lung cancer and performance status 0 or 1 were
randomized to one of the three arms: (A) pemetrexed 500 mg/m2
and carboplatin area under the curve 6 once every 3 weeks for up to
6 cycles with a loading dose of enzastaurin 1125 or 1200 mg
followed by 500 mg daily until disease progression, (B) the same
regimen of pemetrexed-carboplatin without enzastaurin, or (C) do-
cetaxel 75 mg/m2 and carboplatin area under the curve 6 once every
3 weeks for up to six cycles. The primary end point was time to
disease progression (TTP).
Results: Between March 2006 and May 2008, 218 patients were
randomized. Median TTP was 4.6 months for pemetrexed-carbopla-
tin-enzastaurin, 6.0 months for pemetrexed-carboplatin, and 4.1
months for docetaxel-carboplatin (differences not significant). Me-
dian survival was 7.2 months for pemetrexed-carboplatin-enza-
staurin, 12.7 months for pemetrexed-carboplatin, and 9.2 months for
docetaxel-carboplatin (log-rank p  0.05). Compared with the other
arms, docetaxel-carboplatin was associated with lower rates of grade
3 thrombocytopenia and anemia but a higher rate of grade 3 or 4
febrile neutropenia.
Conclusion: There was no difference in TTP between the three
arms, but survival was longer with pemetrexed-carboplatin com-
pared with docetaxel-carboplatin. Enzastaurin did not add to the
activity of pemetrexed-carboplatin.
Key Words: Pemetrexed, Carboplatin, Enzastaurin, NSCLC, Ran-
domized phase II trial.
(J Thorac Oncol. 2010;5: 1963–1969)
Lung cancer is the leading cause of cancer death worldwide,resulting in more deaths than breast, prostate, and colon
cancer combined. In the United States, there will be an estimated
215,000 new cases and 159,000 deaths from cancer of the lung
or bronchus in 2009.1 Approximately 85% of lung cancer
patients will have non-small cell lung cancer (NSCLC); most
will have advanced stage disease at the time of diagnosis, and
5-year survival is less than 10% in this patient population.2,3
Platinum-based doublet chemotherapy is the standard of care for
patients with good performance status (PS) of 0 or 1 based on
modest benefits in survival and quality of life compared with
best supportive care alone.4–7 In otherwise unselected patients,
several large clinical trials have failed to establish a specific
regimen as standard for advanced NSCLC.8–11
Enzastaurin is a selective, oral serine/threonine kinase
inhibitor that targets protein kinase C-beta (PKC-) and the
phosphatidylinositol-3-kinase (PI3K)/AKT pathway to in-
hibit tumor cell proliferation, induce apoptosis, and suppress
tumor-induced angiogenesis.12 PKC and PI3K/AKT are over-
expressed and overactive in lung cancer tissues and cell
lines.13–16 A phase IB clinical trial suggested that the combi-
nation of pemetrexed plus enzastaurin was well tolerated with
preliminary evidence of anticancer activity.17 In a phase II
study of single-agent enzastaurin as second- or third-line
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therapy in patients with metastatic NSCLC, 13% of patients
had disease stabilization for 6 months, and 11% of patients
had prolonged stabilization (up to 20 months).18
Until recently, histologic subtype was not seen as an
important predictor of treatment efficacy, and most trials
included patients without selection by histology.19–21 Subse-
quent to the initiation of the current trial, results from a phase
III trial comparing pemetrexed-cisplatin and gemcitabine-
cisplatin were reported.22 The overall results of the trial
showed that pemetrexed-cisplatin provided similar efficacy
with improved tolerability compared with gemcitabine-cis-
platin. However, a prospectively planned subgroup analysis
by histology showed that survival favored the pemetrexed-
cisplatin arm among patients with adenocarcinoma or large
cell carcinoma (12.6 months versus 10.9 months, p  0.03)
but favored gemcitabine-cisplatin among patients with squa-
mous cell carcinoma (9.4 months versus 10.8 months, p 
0.05). As a result, pemetrexed-cisplatin has been approved by
the Food and Drug Administration as first-line treatment for
patients with locally advanced or metastatic NSCLC and
nonsquamous histology. Two previous phase II trials have
evaluated the combination of pemetrexed-carboplatin.23,24
The phase III TAX 326 trial compared three platinum
combinations of docetaxel-cisplatin, docetaxel-carboplatin,
and vinorelbine-cisplatin. In that trial, docetaxel-carboplatin
was associated with a median survival of 9.4 months.25 The
trial showed that docetaxel-platinum combinations were ef-
fective treatment options in advanced NSCLC. The combi-
nation of docetaxel-carboplatin has not been previously com-
pared with pemetrexed-carboplatin. The current open-label
trial was initiated to compare a reference arm of docetaxel-
carboplatin with two investigational arms of pemetrexed-
carboplatin with and without enzastaurin.
PATIENTS AND METHODS
Patient Eligibility
Patients with a histologic or cytologic diagnosis of
NSCLC with stage IIIB (and pleural effusion) or stage IV
disease were eligible.26 Patients had not received prior sys-
temic chemotherapy, immunotherapy, biologic therapy, or
radiation therapy. Because this trial was initiated before the
treatment-by-histology effect of pemetrexed was known, pa-
tients of all NSCLC histologic types were included. Other
inclusion criteria included measurable disease by Response
Evaluation Criteria in Solid Tumors (RECIST),27 age 18
years or older, an Eastern Cooperative Oncology Group PS of
0 or 1, a life expectancy 12 weeks, and adequate end-organ
function and bone marrow reserve (defined as an absolute
neutrophil count [ANC] 1.5  109/L; platelet count
100  109/L; hemoglobin 8 g/dl; bilirubin the institu-
tional upper limit of normal (ULN); alkaline phosphatase
2.5  ULN; aspartate transaminase and alanine transami-
nase 2.5  ULN; and calculated creatinine clearance
[CrCl] 45 ml/min using the Cockroft and Gault formula).28
Patients with documented central nervous system (CNS)
metastases that were adequately treated and stable for at least
4 weeks were included. Patients were required to use an
appropriate contraceptive method. Prior radiation therapy
was allowed to 25% of the bone marrow.
Exclusion criteria included radiation to the whole pelvis;
serious concomitant systemic disorders (e.g., infection); preg-
nancy or breast-feeding; myocardial infarction within 6 months;
weight loss of10% or 5 kg (whichever was greater) in the past
3 months before study entry; presence of uncontrollable ascites
or pleural effusions; and an inability or unwillingness to take
folate, vitamin B12, or dexamethasone. Patients with CNS
metastases who were receiving warfarin were also excluded.
Treatment Plan
Patients were randomized to one of the following:
pemetrexed and carboplatin with enzastaurin (PCbE), pem-
etrexed and carboplatin (PCb), or docetaxel and carboplatin
(DCb) (see Figure 1). For patients receiving PCbE or PCb,
pemetrexed was administered at 500 mg/m2 over 10 minutes
and followed by carboplatin at an area under the concentra-
tion curve (AUC) of 6 mg/ml/min on day 1 every 3 weeks for
six cycles. For patients receiving PCbE, enzastaurin was
given as a loading dose of 1125 mg (three 125 mg tablets
three times) or 1200 mg (four 100 mg tablets three times) one
week before chemotherapy then subsequently daily as 500
mg until disease progression or unacceptable toxicity. Pa-
tients in the control treatment arm of DCb received docetaxel
at 75 mg/m2 over 60 minutes followed by carboplatin AUC 6
mg/ml/min on day 1 every 3 weeks for six cycles.
On the days immediately preceding, day of, and immedi-
ately after pemetrexed administration, prophylactic dexametha-
sone (4 mg or equivalent twice daily) was administered to
prevent rash. In addition, folic acid (350 to 1000 g or equiv-
alent daily) and vitamin B12 (1000 g, every 9 weeks until 3
weeks after the last dose of pemetrexed) supplementation were
administered. Dexamethasone (8 mg or equivalent twice daily)
was also administered to patients receiving docetaxel.
Hematologic dose adjustments at the start of a subse-
quent cycle of chemotherapy were based on platelet and
neutrophil nadir counts from the preceding cycle of therapy.
Before the start of any cycle, ANC had to be 1.5  109/L
and platelet count 100  109/L. Treatment was delayed to
allow sufficient time for recovery. For patients receiving
FIGURE 1. Study design.
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PCbE or PCb, chemotherapy resumed at 75% of the previous
dose if ANC nadir was 0.5  109/L and chemotherapy
resumed at 50% of the previous dose if platelets were 50 
109/L. For patients receiving DCb, chemotherapy resumed at
75% of the previous dose if the ANC from the previous cycle
was 0.5  109/L for more than 7 days or was accompanied
by fever and platelets were 25 to 50  109/L, if ANC was
0.5  109/L, or if platelets were 25  109/L. Additional
dose adjustment criteria were provided for grade 3 or 4
nonhematologic toxicities. Doses of enzastaurin were to be
omitted in the event of an ANC 0.5  109/L for more than
7 days or 1.0  109/L and accompanied by fever; platelets
25  109/L; a grade 3 or 4 nonhematologic toxicity con-
sidered clinically relevant; or grade 3 or 4 transaminase
elevations.
Any patient who required a dose reduction continued to
receive a reduced dose for the remainder of the study. Any
patient with two prior dose reductions who experienced a
toxicity that would cause a third dose reduction was to be
withdrawn from study chemotherapy. Chemotherapy could
be delayed for up to 42 days to allow a patient sufficient time
to recover from study drug-related toxicity.
Statistical Methods and Study Evaluations
The primary objective of this study was to determine
whether or not time to disease progression (TTP) could be
improved with PCbE or PCb as compared with a control regi-
men of DCb. Based on results from TAX 326 trial, the TTP
associated with DCb was assumed to be 4.5 months.25 To
provide 80% power to detect a relative improvement in TTP of
3 months for either experimental regimen, a minimum of 126
events were required for each pairwise comparison. Therefore,
the target sample size was 70 patients for each treatment regi-
men or 210 patients in total. The one-sided alpha level for each
comparison was 0.025. The planned accrual duration was 36
months, with 12 months of additional follow-up.
TTP was defined as the time from randomization to the
first date of disease progression. For patients who did not
have documented disease progression and did not receive any
other antitumor therapy, TTP was censored at the date of
death or date of last visit. TTP was also censored for patients
who received other antitumor therapy before disease progres-
sion. Secondary end points in this study included overall
survival (OS), response rates (evaluated once every 6 weeks
by RECIST),27 toxicities according to the Common Termi-
nology Criteria Version 3.0,29 resource utilization measured
by hospitalization days and reason for hospitalization, and
quality of life as measured by the Functional Assessment of
Cancer Therapy (FACT)-Lung and FACT-Taxane scales.30,31
Collection of tissue samples was planned; however, too few
were obtained for formal analysis.
OS was defined as the time from the date of random-
ization to the date of death from any cause. OS was censored
at the date of the last follow-up visit for patients who were
still alive. TTP and OS were estimated using the Kaplan-
Meier method.32 For response, progression, and survival data,
two-sided 95% confidence intervals (CIs) were calculated
based on an exact binomial probability. Dose intensity for
pemetrexed, carboplatin, and docetaxel was measured as the
amount of drug administered as a percentage of planned dose.
Compliance with enzastaurin was measured by pill counts,
which indicated whether a patient took at least 75% of
enzastaurin during the preceding cycle of chemotherapy.
This study was performed in accordance with principles
of good clinical practice, applicable laws and regulations, and
the Declaration of Helsinki. Before initiation of the study,
investigators were responsible for obtaining written consent
from participating patients and approval from study sites’
ethical review boards.
RESULTS
Patients and Treatment Administration
Between March 2006 and May 2008, 218 patients were
enrolled in the United States and randomized to one of the three
treatment arms. Patient disposition is shown in Figure 2, and
baseline characteristics are summarized in Table 1. Of particular
note, histologic distributions were not equal across treatment
groups. Compared with the control group of DCb, PCb had a
greater percentage of patients with squamous histology (30%
versus 19%). Distributions for other variables were similar
across treatment groups.
At least one dose of chemotherapy was administered to 67
(93.1%) patients in the PCbE group, 72 of 74 patients in the PCb
group (97.3%), and 70 of 72 patients in the DCb group (97.2%).
The median (range) number of chemotherapy cycles adminis-
tered was 4.0 (1–6) for PCbE, 5.5 (1–6) for PCb, and 4.0 (1–6)
for DCb. Median relative dose intensity was 97.4% for pem-
etrexed and 91.0% for carboplatin in PCbE, 97.7% for pem-
etrexed and 91.9% for carboplatin in PCb, and 99.0% for
docetaxel and 93.4% for carboplatin in DCb. In the PCbE group,
67 of 72 patients received at least one dose of enzastaurin
(93.1%). The most common reasons for study completion in-
cluded completion of protocol-defined therapy (which was not
defined for PCbE but included 45.9% of PCb and 31.9% of DCb
groups), disease progression (65.3% of PCbE, 32.4% of PCb,
and 38.9% of DCb), and adverse event (12.5% of PCbE, 12.2%
of PCb, and 18.1% of DCb). Differences in reasons for study
completion were not significantly different between PCb and
DCb. Average compliance with enzastaurin over six cycles of
chemotherapy was 77.4% in PCbE.
FIGURE 2. CONSORT diagram.
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Efficacy
Primary efficacy outcomes by treatment group are sum-
marized in Table 2. Overall censorship rates across treatment
groups were 23.8% for TTP and 25.2% for OS end points.
Kaplan-Meier curves for TTP and OS are summarized in Figure
3. Median TTPwas 4.6 months (95%CI: 3.2–6.7) for PCbE, 6.0
months (95% CI: 4.6–6.5) for PCb, and 4.1 months (95% CI:
2.6–6.3) for DCb. Differences between individual treatment
groups were not significant, as indicated by log-rank p values.
Median survival was 7.2 months (95% CI: 5.7–11.2) for PCbE,
12.7 months (95% CI: 9.3–17.0) for PCb, and 9.2 months (95%
CI: 5.9–10.7) for DCb. Comparisons between treatment groups
indicated that OS with PCb was significantly longer than with
the control group of DCb (after adjusting for histology, hazard
ratio  0.67; 95% CI: 0.45–0.99).
Overall response rates were not significantly different
among the three regimens (13.6% for PCbE, 22.2% for PCb,
and 27.1% for DCb). Disease control rates (which included
all patients with a complete response, partial response, or
stable disease) were 65.1% for PCbE, 77.8% for PCb, and
57.1% for DCb. The difference between PCb and DCb in
terms of disease control was statistically significant (Fisher’s
exact test p  0.01).
Toxicity
Toxicity profiles of study drug-related events for the
three regimens are summarized in Table 3. In terms of
hematologic toxicity, the rates of grade 3 or 4 thrombocyto-
penia and anemia were greater with PCbE and PCb compared
with DCb. Grade 3 or 4 thrombocytopenia was 5.6% for DCb
and more than 30% for the other two treatment arms; grade 3
or 4 anemia was 1.4% for DCb and more than 13% for the
other two arms. The rate of grade 3 or 4 febrile neutropenia
was greatest with DCb (8.3% versus1.5% for the other two
arms). The rates of grade 3 or 4 nonhematologic toxicities
were generally low. Grade 2 alopecia occurred in 17.1% of
DCb patients compared with less than 5% of patients in the
other two treatment arms.
Poststudy Therapy/Quality of Life
Table 4 summarizes the use of systemic poststudy ther-
apy. Overall, the most commonly used agents poststudy were
erlotonib, docetaxel, carboplatin, and pemetrexed. Final results
from the quality of life analysis were previously presented.33
Using either the FACT-Lung or FACT-Taxane subscales, dif-
ferences in mean change from baseline scores were not statisti-
cally significant across treatment groups. In addition, differences
in classification of patients as improved, stable, or worsened
were not significant across treatment groups.
DISCUSSION
In this randomized, phase II trial of three regimens in
the first-line treatment of stage IIIB/IV NSCLC, differences
in the primary end point, TTP, were not statistically signifi-
cant across treatment arms. Treatment with PCb was associ-
ated with significantly longer OS when compared with DCb
(12.7 months versus 9.2 months, log-rank p  0.05). Com-
pared with the other two arms, DCb was associated with
lower rates of grade 3 thrombocytopenia and anemia but an
increased rate of alopecia and a slightly higher rate of grade
3 or 4 febrile neutropenia. The median number of cycles of
chemotherapy delivered was greater in the PCb arm (5.5)
compared with the DCb arm (4.0).
The disappointing results associated with the PCbE arm
in the current trial are consistent with other recent trials using
enzastaurin in advanced or metastatic NSCLC. Two previous
studies of enzastaurin in advanced NSCLC were terminated
for futility at interim analysis. In the second-line setting, a
phase II trial (N  160) of the combination of pemetrexed
plus enzastaurin did not improve progression-free survival
when compared with pemetrexed plus placebo.34 Similarly, in
the first-line setting, a randomized trial conducted by the
Hoosier Oncology Group among patients with nonsquamous
histology (N  40) failed to show improvement in progres-
sion-free survival for the combination of pemetrexed, carbo-
platin, bevacizumab, and enzastaurin when compared with
pemetrexed, carboplatin, bevacizumab, and placebo.35 Fur-
ther development of enzastaurin in advanced or metastatic
NSCLC is not justified.









Median (range) 67 (43–83) 66 (44–84) 65 (46–79)
Gender, n (%)
Male 41 (57) 41 (55) 42 (58)
Female 31 (43) 33 (45) 30 (42)
Race, n (%)
Caucasian 62 (86) 63 (85) 63 (88)
African descent 5 (7) 11 (15) 8 (11)
Hispanic 5 (7) 0 (0) 1 (1)
ECOG performance
status, n (%)a
0 34 (47) 35 (47) 32 (44)
1 38 (53) 38 (51) 40 (56)
Stage, n (%)
IIIB 6 (8) 5 (7) 6 (8)
IV 66 (92) 69 (93) 66 (92)
Brain metastasis, n (%)
Present 5 (7) 7 (9) 4 (6)
Absent 67 (93) 67 (91) 68 (94)
Histology, n (%)
Adenocarcinoma 46 (64) 43 (58) 43 (60)
Large Cell 2 (3) 3 (4) 3 (4)
Mixed 2 (3) 0 (0) 2 (3)
Squamous 9 (13) 22 (30) 14 (19)
Unknown/NOS 13 (18) 6 (8) 10 (14)
Smoking history




a Performance status information was missing for one patient receiving PCb.
DCb, docetaxel and carboplatin; ECOG, Eastern Cooperative Oncology Group;
NOS, not otherwise specified; PCb, pemetrexed and carboplatin; PCbE, pemetrexed,
carboplatin, and enzastaurin.
Socinski et al. Journal of Thoracic Oncology • Volume 5, Number 12, December 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1966
Results with PCb were notable in light of a 2-year survival
rate of 26.8% (95% CI: 16.6–38.2). Three-year survival was
11.5% (95% CI: 3.2–25.7). This result is interesting as we
continue to strive to identify effective chemotherapy regimens
that will help us to achieve our goals of extending long-term
survival in metastatic NSCLC. However, conclusions with re-
spect to this trial are limited due to the relatively small sample
size associated with the phase II trial design.
Grønberg et al.36 reported the results of a randomized
phase III trial comparing PCb and gemcitabine-carboplatin.
In that trial, 219 patients received PCb, and median survival
was 7.3 months (95% CI: 6.1–8.6) within that group. The
lower survival associated with PCb compared with the cur-
rent trial in the Grønberg et al.36 trial may be partly attributed
to its less restrictive patient selection criteria, which allowed
patients with PS 2, any weight loss, uncontrolled pleural
effusions, and progressive CNS metastases. The Grønberg et
al. trial also used a lower dose of carboplatin (AUC 5) than
the current trial and used prespecified dose reductions based
on age.
FIGURE 3. A, Time to disease progression. B, Overall survival. DCb, docetaxel and carboplatin; PCb, pemetrexed and carbo-
platin; PCbE, pemetrexed, carboplatin, and enzastaurin.







Time to disease progression
Censorship, % 27.8 20.3 23.6
Median, mo (95% CI) 4.6 (3.2–6.7) 6.0 (4.6–6.5) 4.1 (2.6–6.3)
Log-rank pairwise p value 0.40 0.19 Referent
Overall survival
Censorship, % 22.2 27.0 26.4
Hazard ratiosa (95% CI) 0.97 (0.67, 1.42) 0.67 (0.45, 0.99) Referent
Median, mo (95% CI) 7.2 (5.7, 11.2) 12.7 (9.3, 17.0) 9.2 (5.9, 10.7)
1-yr survival rate, % (95% CI) 37.4 (26.0, 48.8) 52.7 (40.4, 63.7) 32.6 (21.5, 44.2)
2-yr survival rate, % (95% CI) 15.0 (7.0, 25.7) 26.8 (16.6, 38.2) 18.9 (10.2, 29.6)
3-yr survival rate, % (95%) CI 0.0 11.5 (3.2, 25.7) 0.0
Log-rank pairwise p value 0.87 0.05 Referent
Response rate
No. assessed for response 66 72 70
Complete response, n (%) 0 (0.0) 2 (2.8) 0 (0.0)
Partial response, n (%) 9 (13.6) 14 (19.4) 19 (27.1)
Stable disease, n (%) 34 (51.5) 40 (55.6) 21 (30.0)
Progressive disease, n (%) 11 (16.7) 10 (13.9) 10 (14.3)
Unknown/not done, n (%) 12 (18.2) 6 (8.3) 20 (28.5)
Disease control rate,b n (%) 43 (65.1) 56 (77.8) 40 (57.1)
p value for disease control rate 0.38 0.01 Referent
a Hazard ratios were obtained using Cox model for each pair with adjustment for histologic subgroup.
b Disease control rate included patients with complete response, partial response, and stable disease.
CI, confidence interval; DCb, docetaxel and carboplatin; PCb, pemetrexed and carboplatin; PCbE, pemetrexed, carboplatin,
and enzastaurin.
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Phase II trials of PCb conducted at M. D. Anderson
Cancer Center (N  50)23 and in Europe (N  38)24 produced
median survival times of 13.5 months (95% CI: 10.1–16.8) and
10.5 months (95% CI: 7.6–12.8), respectively. Both those trials
excluded patients with PS 2, significant weight loss, uncon-
trolled pleural effusions, and documented brain metastases.
Histologic subtype has not historically been an important
predictor of treatment efficacy, and retrospective analyses of
Eastern Cooperative Oncology Group 1594 and Southwest On-
cology Group trials suggest that most chemotherapeutic agents
do not exhibit a preferential treatment effect by patient histol-
ogy.37,38 The phase III first-line trial of pemetrexed-cisplatin22 as
well as phase III trials of single-agent pemetrexed in the second-
line39 and maintenance settings,40 however, suggest that pem-
etrexed has preferential activity in nonsquamous patients. In the
current trial, the PCb arm had a greater proportion of patients
with squamous histology than the DCb arm.
Research to further evaluate PCb with other agents is
ongoing. A recent phase II study of initial therapy with PCb
and bevacizumab followed by maintenance pemetrexed and
bevacizumab resulted in an objective response rate of 55%
and a median survival of 14.1 months (95% CI: 10.8–19.6).41
That regimen is currently being tested in the phase III setting
against a regimen of paclitaxel, carboplatin, and bevaciz-
umab followed by maintenance bevacizumab in a trial
(NCT00762034) that has a planned accrual of 900 patients.42
A second ongoing phase III trial (NCT00948675) with a
planned sample size of 360 is comparing paclitaxel, carbo-
platin, and bevacizumab followed by maintenance bevaci-
zumab to PCb followed by maintenance pemetrexed.43
Results from this trial with respect to OS should be
interpreted cautiously in light of the negative findings with
respect to the primary end point and the limitations in
generating conclusions from phase II designs. These results,
however, support the continued evaluation of PCb with or
without novel agents in stage IIIB/IV NSCLC.
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TABLE 3. Toxicity Summary of Drug-Related Events
Adverse Event
PCbE (N  72) PCb (N  74) DCb (N  72)
Any
(Grade 1–4) Grade 3 Grade 4
Any
(Grade 1–4) Grade 3 Grade 4
Any
(Grade 1–4) Grade 3 Grade 4
Neutropenia 24 (33.3) 5 (6.9) 4 (5.6) 29 (39.2) 11 (14.9) 2 (2.7) 21 (29.2) 9 (12.5) 5 (6.9)
Febrile neutropenia 1 (1.4) 1 (1.4) 0 (0.0) 1 (1.4) 1 (1.4) 0 (0.0) 6 (8.3) 4 (5.6) 2 (2.8)
Thrombocytopenia 37 (51.4) 16 (22.2) 8 (11.1) 43 (58.1) 18 (24.3) 6 (8.1) 17 (23.6) 3 (4.2) 1 (1.4)
Anemia 33 (45.8) 10 (13.9) 0 (0.0) 48 (64.8) 14 (18.9) 1 (1.4) 34 (47.2) 1 (1.4) 0 (0.0)
Anorexia 9 (12.5) 2 (2.8) 0 (0.0) 10 (13.5) 0 (0.0)) 0 (0.0) 14 (19.4) 1 (1.4) 0 (0.0)
Diarrhea 14 (19.4) 3 (4.2) 0 (0.0) 8 (10.8) 1 (1.4) 0 (0.0) 15 (20.8) 4 (5.6) 0 (0.0)
Elevated ALT 3 (4.2) 1 (1.4) 0 (0.0) 7 (9.5) 0 (0.0) 0 (0.0) 1 (1.4) 0 (0.0) 0 (0.0)
Thrombosis 10 (13.9) 6 (9.0) 3 (4.5) 4 (5.4) 1 (1.4) 2 (2.8) 6 (8.3) 3 (4.3) 3 (4.3)
Fatigue 25 (34.7) 3 (4.2) 0 (0.0) 31 (41.9) 2 (2.7) 0 (0.0) 31 (43.1) 4 (5.6) 0 (0.0)
Hypersensitivity 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 6 (8.3) 3 (4.2) 0 (0.0)
Nausea 33 (45.8) 1 (1.4) 0 (0.0) 30 (40.5) 3 (4.1) 0 (0.0) 22 (30.1) 2 (2.8) 0 (0.0)
Vomiting 15 (20.8) 3 (4.2) 0 (0.0) 14 (18.9) 2 (2.7) 0 (0.0) 13 (18.1) 2 (2.8) 0 (0.0)
Alopecia (grade 2) 1 (1.5) 3 (4.2) 12 (17.1)
Values are given as n (%).
ALT, alanine aminotransferase; DCb, docetaxel and carboplatin; PCb, pemetrexed and carboplatin; PCbE, pemetrexed, carboplatin, and enzastaurin.







Patients with any systemic
poststudy chemotherapy
42 (58.3) 42 (56.7) 33 (45.8)
Bevacizumab 10 (13.9) 5 (6.8) 5 (6.9)
Carboplatin 12 (16.7) 10 (13.5) 9 (12.5)
Cisplatin 1 (1.4) 3 (4.1) 0 (0.0)
Docetaxel 15 (20.8) 15 (20.3) 4 (5.6)
Erlotinib 10 (13.9) 9 (12.2) 11 (15.3)
Gemcitabine 2 (2.8) 2 (2.7) 4 (5.6)
Paclitaxel 9 (12.5) 7 (9.5) 3 (4.2)
Pemetrexed 4 (5.6) 8 (10.8) 11 (15.3)
Values are given as n (%).
DCb, docetaxel and carboplatin; PCb, pemetrexed and carboplatin; PCbE, pem-
etrexed, carboplatin, and enzastaurin.
Socinski et al. Journal of Thoracic Oncology • Volume 5, Number 12, December 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1968
5. Grilli R, Oxman AD, Julian JA. Chemotherapy for advanced non-small-
cell lung cancer: how much benefit is enough? J Clin Oncol 1993;11:
1866–1872.
6. Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive
care in advanced non-small-cell lung cancer. Results of a meta-analysis
of the literature. Chest 1994;106:861–865.
7. Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced
non small cell lung cancer: a meta-analysis. Lancet 1993;342:19–21.
8. Kortsik C, Albrecht P, Elmer A. Gemcitabine and carboplatin in patients
with locally advanced or metastatic non-small cell lung cancer: a
prospective phase II study. Lung Cancer 2003;40:85–90.
9. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carbopla-
tin versus gemcitabine plus paclitaxel in advanced non-small-cell lung
cancer: a phase III randomized trial. J Clin Oncol 2002;20:3578–3585.
10. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial
comparing three platinum-based doublets in advanced non-small-cell
lung cancer. J Clin Oncol 2002;20:4285–4291.
11. Schiller JH, Harrington D, Belani CP, et al. Comparison of four che-
motherapy regimens for advanced non-small-cell lung cancer. N Engl
J Med 2002;346:92–98.
12. Graff JR, McNulty AM, Hanna KR, et al. The protein kinase Cbeta-
selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling
through the AKT pathway, induces apoptosis, and suppresses growth of
human colon cancer and glioblastoma xenografts. Cancer Res 2005;65:
7462–7469.
13. Barr LF, Campbell SE, Baylin SB. Protein kinase C-beta 2 inhibits
cycling and decreases c-myc-induced apoptosis in small cell lung cancer
cells. Cell Growth Differ 1997;8:381–392.
14. Clark AS, West KA, Blumberg PM, et al. Altered protein kinase C
(PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes
cellular survival and chemotherapeutic resistance. Cancer Res 2003;63:
780–786.
15. Lahn M, McClelland P, Ballard D, et al. Immunohistochemical detection
of protein kinase C-beta (PKC-beta) in tumour specimens of patients
with non-small cell lung cancer. Histopathology 2006;49:429–431.
16. Tang JM, He QY, Guo RX, et al. Phosphorylated Akt overexpression
and loss of PTEN expression in non-small cell lung cancer confers poor
prognosis. Lung Cancer 2006;51:181–191.
17. Hanauske AR, Lahn M, Musib LC, et al. Phase Ib safety and pharma-
cokinetic evaluation of daily and twice daily oral enzastaurin in combi-
nation with pemetrexed in advanced/metastatic cancer. Ann Oncol 2009;
20:1565–1575.
18. Oh Y, Herbst RS, Burris H, et al. Enzastaurin, an oral serine/threonine
kinase inhibitor, as second- or third-line therapy of non-small-cell lung
cancer. J Clin Oncol 2008;26:1135–1141.
19. Gridelli C. Histology-based treatment: a new scenario in the manage-
ment of advanced nonsmall cell lung cancer. Curr Opin Oncol 2009;21:
97–98.
20. Gridelli C, Rossi A, de Marinis F. Pattern of care for advanced non-small
cell lung cancer in the era of histology-based treatment: a survey of the
Italian Association of Thoracic Oncology (AIOT). Lung Cancer 2010;
67:339–342.
21. Hirsch F, Sperafico A, Novello S, et al. The prognostic and predictive
role of histology in advanced non-small cell lung cancer: a literature
review. J Thorac Oncol 2009;4:1042–1043.
22. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing
cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemother-
apy-naive patients with advanced-stage non-small-cell lung cancer.
J Clin Oncol 2008;26:3543–3551.
23. Zinner RG, Fossella FV, Gladish GW, et al. Phase II study of pem-
etrexed in combination with carboplatin in the first-line treatment of
advanced nonsmall cell lung cancer. Cancer 2005;104:2449–2456.
24. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with
oxaliplatin or carboplatin as first-line treatment in advanced non-small
cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer
Res 2005;11:690–696.
25. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational,
phase III study of docetaxel plus platinum combinations versus vinorel-
bine plus cisplatin for advanced non-small-cell lung cancer: the TAX
326 study group. J Clin Oncol 2003;21:3016–3024.
26. Fleming I, Cooper J, Henson D. American Joint Committee on Cancer
Staging Manual, 5th Ed. Philadelphia, PA: Lippincott-Raven, 1998.
27. Therasse P, Arbuck S, Eisenhauer E. New guidelines to evaluate the
response to treatment in solid tumors. European Organization for Re-
search and Treatment of Cancer, National Cancer Institute of the United
States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;
92:205–216.
28. Cockcroft DW, Gault MH. Prediction of creatinine clearance from
serum creatinine. Nephron 1976;16:31–41.
29. Common Terminology Criteria for Adverse Events v3.0 (CTCAE),
Cancer Therapy Evaluation Program, 2003.
30. Cella D, Peterman A, Hudgens S, et al. Measuring the side effects of
taxane therapy in oncology: the functional assessment of cancer therapy-
taxane (FACT-taxane). Cancer 2003;98:822–831.
31. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the
Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of
life instrument. Lung Cancer 1995;12:199–220.
32. Kaplan E, Meier P. Nonparametric estimation of incomplete observa-
tions. J Am Stat Assoc 1958;53:457–481.
33. Raju R, Socinski M, Stichcombe T, et al. A prospective evaluation of
quality of life (QOL) in a phase II trial of pemetrexed (P) plus
carboplatin (Cb)  enzastaurin (E) versus docetaxel (D) plus Cb as
first-line treatment of patients (pts) with advanced non-small cell lung
cancer (NSCLC). J Clin Oncol, 2009 ASCO Annual Meeting Proceed-
ings. 2009;27(Suppl 18):19050 (abstract).
34. von Pawel J, Barlesi F, Soria J, et al. A phase II, double-blind,
randomized study of enzastaurin versus placebo concurrently with pem-
etrexed as second-line therapy in patients with advanced or metastatic
non-small cell lung cancer. 13th World Conference on Lung Cancer,
2009: D2.7 (abstract).
35. Casey E, Harb W, Bradford D, et al. Randomized, double-blind, multi-
center, phase II study of pemetrexed (PEM), carboplatin (CARBO),
bevacizumab (BEV) with enzastaurin (ENZ) or placebo (PBO) in
chemo-naïve patients with stage IIIB/IV non-small cell lung cancer
(NSCLC): Hoosier Oncology Group (HOG) LUN06-116. J Clin Oncol,
2009 ASCO Annual Meeting Proceedings. 2009;27(Suppl 18):8035
(abstract).
36. Grønberg BH, Bremnes RM, Fløtten Ø, et al. Phase III study by the
Norwegian lung cancer study group: pemetrexed plus carboplatin com-
pared with gemcitabine plus carboplatin as first-line chemotherapy in
advanced non-small-cell lung cancer. J Clin Oncol 2009;27:3217–3224.
37. Chansky K, Mack P, Crowley J, et al. Chemotherapy outcomes by
histologic subtype of non-small cell lung cancer (NSCLC): analysis of
the SWOG database for antimicrotubule (AMT)-platinum therapy. 13th
World Conference on Lung Cancer, 2009: B2.7 (abstract).
38. Hoang T, Dahlberg S, Schiller J, et al. Does histology predict survival of
advanced non-small cell lung cancer (NSCLC) treated with standard
platin-based chemotherapy? Retrospective analysis of E1594. 13th
World Conference on Lung Cancer, 2009: PD6.4.1 (abstract).
39. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of
pemetrexed according to NSCLC histology: a review of two Phase III
studies. Oncologist 2009;14:253–263.
40. Belani C, Brodowicz T, Ciuleanu T, et al. Maintenance pemetrexed
(Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC:
a randomized phase III study in advanced non-small cell lung cancer
(NSCLC). J Clin Oncol, 2009 ASCO Annual Meeting Proceedings.
2009;27(Suppl 18):CRA8000 (abstract).
41. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed
and carboplatin plus bevacizumab with maintenance pemetrexed and
bevacizumab as first-line therapy for nonsquamous non-small-cell lung
cancer. J Clin Oncol 2009;27:3284–3289.
42. Patel JD, Bonomi P, Socinski MA, et al. Treatment rationale and study
design for the pointbreak study: a randomized, open-label phase III study
of pemetrexed/carboplatin/bevacizumab followed by maintenance pem-
etrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab fol-
lowed by maintenance bevacizumab in patients with stage IIIB or IV
nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009;10:
252–256.
43. Zinner RG, Saxman SB, Peng G, et al. Treatment rationale and study
design for a randomized trial of pementrexed/carboplatin followed by
maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab fol-
lowed by maintenance bevacizumab in patients with advanced non-
small-cell lung cancer of nonsquamous histology. Clin Lung Cancer
2010;11:352–357.
Journal of Thoracic Oncology • Volume 5, Number 12, December 2010 Treatment of Patients with Stage IIIB/IV NSCLC
Copyright © 2010 by the International Association for the Study of Lung Cancer 1969
